Table 16.

Tabular summary

Fumaric acid esters
First approved in Germany	1995 (Psoriasis vulgaris)
Recommended control parameters	Serum creatinine, transaminases/γGT, complete blood count including differential blood count, urinanalysis
Recommended initial dosage	According to recommended dosage regimen see Table 17
Recommended maintenance dosage	Individually adapted dosage
Expected beginning of clinical effect	After approximately 6 weeks
Response rate	PASI 75 in 50–70% of the patients at the end of the induction phase after 16 weeks (LE 2)
Important contraindications (limited selection)	Chronic diseases of the gastrointestinal tract and/or the kidneys and chronic diseases, which are accompanied by an impairment of the leukocyte count or functions, malignant diseases, pregnancy and nursing
Important ADRs (limited selection)	Gastrointestinal complaints, flush, lymphopenia, eosinophilia
Important drug interactions	None known
Other	–